The Fight - Last month, ViiV revealed results from two studies, pairing its own cabotegravir with Johnson & Johnson’s rilpivirine (branded as Edurant). When given once every four weeks, the drugs can maintain viral suppression in HIV-positive adults as well as a standard three-drug regimen taken daily. The data will be part of the approval application ViiV submits to regulatory authorities later this year, reports hivplusmag.com.

Read More...

 

Mailing List

Contribute!